Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials

European Journal of Cancer

Volumn 54, Issue , 2016, Pages 57-63

  Kroep, J R ^a   Charehbili, A ^a   Coleman, R E ^b   Aft, R L ^c   Hasegawa, Y ^d   Winter, M C ^b   Weilbaecher, K ^c   Akazawa, K ^e   Hinsley, S ^f   Putter, H ^a   Liefers, G J ^a   Nortier, J W R ^a   Kohno, N ^g  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d National Hospital Organization   (Japan)

^e NIIGATA UNIVERSITY   (Japan)

^f Clinical Trials Research Unit   (United Kingdom)

^g KOBE KAISEI HOSPITAL   (Japan)

Author keywords

Bisphosphonates; Breast cancer; Chemotherapy; Neoadjuvant; Pathological complete response; Zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MENOPAUSE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; PATHOLOGICAL COMPLETE RESPONSE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; LYMPH NODE METASTASIS; MORTALITY; NEOADJUVANT THERAPY; PROCEDURES; RISK FACTOR; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84951127280     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.10.011     Document Type: Article

References (24)

1. Early Breast Cancer Trialists' Collaborative Group Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Lancet 386 10001 2015 Oct 3 1353 1361
2. R.E. Coleman, M.C. Winter, D. Cameron, R. Bell, D. Dodwell, M.M. Keane, and et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer Br J Cancer 102 7 2010 Mar 30 1099 1105
3. R. Aft, M. Naughton, K. Trinkaus, M. Watson, L. Ylagan, M. Chavez-MacGregor, and et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial Lancet Oncol 11 5 2010 May 421 428
4. J. Horiguchi, Y. Hasegawa, D. Miura, T. Ishikawa, H. Mitsuhiro, M. Hayashi, and et al. A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer Abstract 1029 ASCO Annual Meeting 2013
5. A. Charehbili, S. van de Ven, V.T. Smit, E.M. Meershoek-Klein-Kranenbarg, N.A. Hamdy, H. Putter, and et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2 negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01) Ann Oncol 2014 Feb 27
6. P.D. Ottewell, H.K. Brown, M. Jones, T.L. Rogers, S.S. Cross, N.J. Brown, and et al. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice Breast Cancer Res Treat 133 2 2012 Jun 523 536
7. G. von Minckwitz, M. Untch, J.U. Blohmer, S.D. Costa, H. Eidtmann, P.A. Fasching, and et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 15 2012 May 20 1796 1804
8. M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, D. Heck, C. Menzel, and et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Lancet Oncol 12 7 2011 Jul 631 641
9. R.E. Coleman, H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, M. Keane, and et al. Breast-cancer adjuvant therapy with zoledronic acid N Engl J Med 365 15 2011 Oct 13 1396 1405
10. P. Hadji, R. Coleman, M. Gnant, and J. Green The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis Ann Oncol 23 11 2012 Nov 2782 2790
11. M.C. Winter, I. Holen, and R.E. Coleman Exploring the anti-tumour activity of bisphosphonates in early breast cancer Cancer Treat Rev 34 5 2008 Aug 453 475
12. M.N. Weitzmann, and R. Pacifici Estrogen deficiency and bone loss: an inflammatory tale J Clin Invest 116 5 2006 May 1186 1194
13. P. Allavena, and A. Mantovani Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment Clin Exp Immunol 167 2 2012 Feb 195 205
14. E.M. Dijkgraaf, M. Heusinkveld, B. Tummers, L.T. Vogelpoel, R. Goedemans, V. Jha, and et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment Cancer Res 73 8 2013 Apr 15 2480 2492
15. T.L. Rogers, and I. Holen Tumour macrophages as potential targets of bisphosphonates J Transl Med 9 2011 177
16. E. Rietkotter, K. Menck, A. Bleckmann, K. Farhat, M. Schaffrinski, M. Schulz, and et al. Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion Oncotarget 4 9 2013 Sep 1449 1460
17. S. Junankar, G. Shay, J. Jurczyluk, N. Ali, J. Down, N. Pocock, and et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer Cancer Discov 2014 Oct 13
18. P.D. Ottewell, H. Monkkonen, M. Jones, D.V. Lefley, R.E. Coleman, and I. Holen Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer J Natl Cancer Inst 100 16 2008 Aug 20 1167 1178
19. P. Fournier, S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, M. Colombel, and et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 22 2002 Nov 15 6538 6544
20. V. Stresing, P.G. Fournier, A. Bellahcene, I. Benzaid, H. Monkkonen, M. Colombel, and et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase Bone 48 2 2011 Feb 259 266
21. D. Santini, B. Vincenzi, S. Galluzzo, F. Battistoni, L. Rocci, O. Venditti, and et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients Clin Cancer Res 13 15 Pt 1 2007 Aug 1 4482 4486
22. D. Santini, B. Vincenzi, G. Dicuonzo, G. Avvisati, C. Massacesi, F. Battistoni, and et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients Clin Cancer Res 9 8 2003 Aug 1 2893 2897
23. M.C. Winter, C. Wilson, S.P. Syddall, S.S. Cross, A. Evans, C.E. Ingram, and et al. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer - a randomized biomarker pilot study Clin Cancer Res 19 10 2013 May 15 2755 2765
24. Website. Clinicaltrials.gov. [accessed 20.11.14].